Relationship between perioperative oncological evaluation and recurrence using circulating tumor DNA with KRAS mutation in patients with colorectal cancer

被引:2
作者
Hayashi, Takaomi [1 ]
Yoshida, Yoichiro [1 ]
Yamada, Teppei [1 ]
Tanaka, Keita [1 ]
Shimaoka, Hideki [1 ]
Kajitani, Ryuji [1 ]
Munechika, Taro [1 ]
Nagano, Hideki [1 ]
Matsumoto, Yoshiko [1 ]
Komono, Akira [1 ]
Sakamoto, Ryohei [1 ]
Aisu, Naoya [1 ]
Yoshimatsu, Gumpei [1 ]
Yoshimura, Fumihiro [1 ]
Hasegawa, Suguru [1 ]
机构
[1] Fukuoka Univ, Dept Gastroenterol Surg, Fac Med, Fukuoka, Japan
来源
CANCER MEDICINE | 2022年 / 11卷 / 16期
关键词
circulating tumor DNA; colorectal cancer; digital PCR; KRAS; liquid biopsy; PROGNOSTIC VALUE; CELLS; PLASMA; SERUM;
D O I
10.1002/cam4.4677
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background The detection of circulating tumor DNA (ctDNA) in colorectal cancer (CRC) by liquid biopsy may have prognostic information. In this perioperative study, we evaluate if there is a relationship between mutant allele frequency (MAF) of Kirsten rat sarcoma viral oncogene homolog (KRAS) and tumor recurrence and how that could be useful in the early detection of recurrence. Methods Among 304 cases of colorectal cancer surgery, ctDNA was sampled from the perioperative blood of 84 patients with CRC with KRAS mutation (exon 4 p.A146T, exon 4 p.A146V, exon 2 p.G12A, exon 2 p.G12C, exon 2 p.G12D, exon 2 p.G12S, exon 2 p.G12V, exon 2 p.G13D, exon 3 p.Q61H) and analyzed using the digital polymerase chain reaction system. The median observation period was 26 months. Results Although the relationship between the perioperative MAF of KRAS and recurrence was not proved, tumor diameter, tumor depth, and stage were correlated with the preoperative MAF of KRAS (p = 0.034, p = 0.002, p = 0.008). However, tumor diameter, tumor depth, and stage did not correlate with MAF of KRAS at postoperative day 30. Conclusions In this study, pathological tumor size, tumor depth, and stage were correlated with preoperative MAF of KRAS, but it was unreliable to predict recurrence by detection of ctDNA with KRAS mutation in the perioperative period of colorectal surgery.
引用
收藏
页码:3126 / 3135
页数:10
相关论文
共 50 条
  • [21] The diagnostic accuracy of circulating free DNA for the detection of KRAS mutation status in colorectal cancer: A meta-analysis
    Xie, Wenli
    Xie, Li
    Song, Xianrang
    CANCER MEDICINE, 2019, 8 (03): : 1218 - 1231
  • [22] Detection of KRAS mutations in circulating tumour DNA from plasma and urine of patients with colorectal cancer
    Ohta, Ryo
    Yamada, Takeshi
    Sonoda, Hiromichi
    Matsuda, Akihisa
    Shinji, Seiichi
    Takahashi, Goro
    Iwai, Takuma
    Takeda, Kohki
    Ueda, Koji
    Kuriyama, Sho
    Miyasaka, Toshimitsu
    Yokoyama, Yasuyuki
    Hara, Keisuke
    Yoshida, Hiroshi
    EJSO, 2021, 47 (12): : 3151 - 3156
  • [23] Oncological evaluation in the perioperative period using cfDNA with BRAF V600E mutation in patients with colorectal cancer
    Tanaka, Keita
    Yoshida, Yoichiro
    Yamada, Teppei
    Hayashi, Takaomi
    Shimaoka, Hideki
    Yoshimura, Fumihiro
    Kajitani, Ryuji
    Munechika, Taro
    Matsumoto, Yoshiko
    Nagano, Hideki
    Komono, Akira
    Sakamoto, Ryohei
    Nakashima, Ryo
    Aisu, Naoya
    Yoshimatsu, Gumpei
    Hasegawa, Suguru
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [24] Evaluation of circulating tumor cells in colorectal cancer using flow cytometry
    Musina, Ana-Maria
    Zlei, Mihaela
    Mentel, Mihaela
    Scripcariu, Dragos-Viorel
    Stefan, Madalina
    Anitei, Maria-Gabriela
    Filip, Bogdan
    Radu, Iulian
    Gavrilescu, Mihaela-Madalina
    Panuta, Andrian
    Buna-Arvinte, Mihaela
    Cordun, Cristiana-Ioana
    Predescu, Dragos-Valentin
    Scripcariu, Viorel
    Hutanu, Ionut
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2021, 49 (09)
  • [25] Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer
    Nakamura, Yoshiaki
    Yoshino, Takayuki
    ONCOLOGIST, 2018, 23 (11) : 1310 - 1318
  • [26] Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA
    Benesova, Lucie
    Halkova, Tereza
    Ptackova, Renata
    Semyakina, Anastasiya
    Menclova, Katerina
    Pudil, Jiri
    Ryska, Miroslav
    Levy, Miroslav
    Simsa, Jaromir
    Pazdirek, Filip
    Hoch, Jiri
    Blaha, Milan
    Minarik, Marek
    WORLD JOURNAL OF GASTROENTEROLOGY, 2019, 25 (48) : 6939 - 6948
  • [27] Monitoring colorectal cancer following surgery using plasma circulating tumor DNA
    Sun, Xiao
    Huang, Tanxiao
    Cheng, Fangsheng
    Huang, Kaibing
    Liu, Ming
    He, Wan
    Li, Mingwei
    Zhang, Xiaoni
    Xu, Mingyan
    Chen, Shifu
    Xia, Ligang
    ONCOLOGY LETTERS, 2018, 15 (04) : 4365 - 4375
  • [28] Detection of KRAS mutations in circulating tumor cells from patients with metastatic colorectal cancer
    Buim, Marcilei E. C.
    Fanelli, Marcello F.
    Souza, Virgilio S.
    Romero, Juliana
    Abdallah, Emne A.
    Mello, Celso A. L.
    Alves, Vanessa
    Ocea, Luciana M. M.
    Mingues, Natalia B.
    Barbosa, Paula N. V. P.
    Tyng, Chiang J.
    Chojniak, Rubens
    Chinen, Ludmilla T. D.
    CANCER BIOLOGY & THERAPY, 2015, 16 (09) : 1289 - 1295
  • [29] Droplet digital PCR of circulating tumor cells from colorectal cancer patients can predict KRAS mutations before surgery
    Denis, Jerome Alexandre
    Patroni, Alexia
    Guillerm, Erell
    Pepin, Dominique
    Benali-Furet, Naoual
    Wechsler, Janine
    Manceau, Gilles
    Bernard, Maguy
    Coulet, Florence
    Larsen, Annette K.
    Karoui, Mehdi
    Lacorte, Jean-Marc
    MOLECULAR ONCOLOGY, 2016, 10 (08): : 1221 - 1231
  • [30] Assessing the Impact of Circulating Tumor DNA (ctDNA) in Patients With Colorectal Cancer: Separating Fact From Fiction
    Gabriel, Emmanuel
    Bagaria, Sanjay P.
    FRONTIERS IN ONCOLOGY, 2018, 8